It may strengthen your immune system and relieve oxidative stress prior to travel, life events, or exposure to sick family members or friends
3.1.2 Other PEDs This group included other substances prohibited by WADA, such as non-approved substances (BPC-157) from Section S0, other anabolic agents (clenbuterol and SARMs) from Subsection S0, S1.2, peptide hormones and their releasing factors (AOD-9604, hGH 176-191, CJC-1295, ibutamoren, ipamorelin, and growth hormone-releasing peptide) from S2.2, growth factors and growth factor modulators (thymosin-4 and its derivative TB-500) from S2.3, beta-2 agonists (salbutamol and indacaterol) from S3, metabolic modulators (meldonium, GW1516, SR9009, SR9011, and insulins) from Section S4.4, and thyroid hormones
Suboptimal weight loss
Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides